Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3001718 | 0.81 | PNMT (0.56) | SLC6A4SLC6A2SLC6A3TAAR1ALDH1A1 | |
| SCHEMBL296089 | 0.80 | TAAR1 (0.63) | SLC6A4SLC6A2SLC6A3TAAR1LMNA | |
| SCHEMBL21345495 | 0.79 | LMNA (0.46) | LMNAHPGDALOX12P2RX7ALDH1A1 | |
| SCHEMBL1254035 | 0.78 | TP53 (0.44) | SLC6A4SLC6A2SLC6A3P2RX7HTR2A | |
| SCHEMBL13886573 | 0.78 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3TAAR1P2RX7 | |
| SCHEMBL23202539 | 0.77 | CHRM2 (0.49) | SLC6A4SLC6A3LMNAHPGDALOX12 | |
| SCHEMBL18887689 | 0.77 | P2RX7 (0.43) | LMNAHPGDALOX12P2RX7ALDH1A1 | |
| SCHEMBL3126847 | 0.77 | P2RX7 (0.56) | LMNAHPGDALOX12P2RX7 | |
| Hydrochloric Acid SCHEMBL6252762 | 0.76 | SLC6A2 (0.46) | SLC6A4SLC6A2SLC6A3TAAR1P2RX7 | |
| SCHEMBL736962 | 0.76 | GLA (0.53) | P2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021072203-A1 | TGFBETAR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021011834-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2019170086-A1 | ACYL-SUBSTITUTED OXAZINO-QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | 北京赛特明强医药科技有限公司 | 2019-09-12 | — | — | WO | disclosed |
| US-20120016117-A1 | INDAZOLEPROPIONIC ACID AMIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120016117-A1 | INDAZOLEPROPIONIC ACID AMIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016117-A1 | INDAZOLEPROPIONIC ACID AMIDE COMPOUND | SCN9A, SCN1A, SCN1B | SLC6A4 3834/4885SLC6A2 4005/4885SLC6A3 3632/4885 |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | SLC6A4 2125/4885SLC6A2 3228/4885SLC6A3 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.